You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMifepristone
Accession NumberDB00834  (APRD00432)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).

Structure
Thumb
Synonyms
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
Corlux
Mifegyne
Mifeprex
Mifepriston
Mifepristona
Mifépristone
Mifepristonum
RU-486
RU486
External Identifiers
  • RU-38486
  • RU-486
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Korlymtablet300 mg/1oralCorcept Therapeutics Inc2012-02-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
CorluxCorcept Therapeutics Incorporated
MefipilAbbott
MifegyneExelgyn Laboratories
MifeprexDanco Laboratories
Brand mixtures
NameLabellerIngredients
MifegymisoLinepharma International Limited
SaltsNot Available
Categories
UNII320T6RNW1F
CAS number84371-65-3
WeightAverage: 429.5937
Monoisotopic: 429.266779369
Chemical FormulaC29H35NO2
InChI KeyInChIKey=VKHAHZOOUSRJNA-GCNJZUOMSA-N
InChI
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
IUPAC Name
(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1,6-dien-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassOxosteroids
Direct ParentOxosteroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • Substituted aniline
  • Dialkylarylamine
  • Aniline
  • Benzenoid
  • Ynone
  • Monocyclic benzene moiety
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
PharmacodynamicsMifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Mechanism of actionThe anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
AbsorptionThe absolute bioavailability of a 20 mg oral dose is 69%
Volume of distributionNot Available
Protein binding98% (bound to plasma proteins, albumin and a 1-acid glycoprotein)
Metabolism

Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.

Route of eliminationFecal: 83%; Renal: 9%.
Half life18 hours
ClearanceNot Available
ToxicityNearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7135
Caco-2 permeable+0.6716
P-glycoprotein substrateSubstrate0.643
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7606
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.8334
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6293
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6129
Ames testNon AMES toxic0.856
CarcinogenicityNon-carcinogens0.825
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity2.7705 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9177
hERG inhibition (predictor II)Non-inhibitor0.6879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Danco laboratories llc
Packagers
  • Danco Labs LLC
Dosage forms
FormRouteStrength
Tabletoral300 mg/1
Kit; tabletbuccal; oral
Prices
Unit descriptionCostUnit
Mifeprex 200 mg tablet90.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-196 °CFDA Label
water solubilityPoorly solubleFDA Label
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00336 mg/mLALOGPS
logP5.33ALOGPS
logP5.13ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)12.87ChemAxon
pKa (Strongest Basic)4.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity132.58 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Narendra Joshi, Anil Khile, Nitin Pradhan, “Novel polymorph form M of mifepristone and process for its preparation.” U.S. Patent US20070105828, issued May 10, 2007.

US20070105828
General References
  1. Fiala C, Gemzel-Danielsson K: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006 Jul;74(1):66-86. Epub 2006 May 19. Pubmed
  2. Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003 Dec;68(6):421-6. Pubmed
  3. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun;11(3):293-307. Epub 2005 Mar 24. Pubmed
  4. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. Pubmed
  5. Piaggio G, von Hertzen H, Heng Z, Bilian X, Cheng L: Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003 Dec;68(6):447-52. Pubmed
External Links
ATC CodesG03XB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (46.5 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Mifepristone.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Mifepristone.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Mifepristone.
ado-trastuzumab emtansineThe serum concentration of ado-trastuzumab emtansine can be increased when it is combined with Mifepristone.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Mifepristone.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Mifepristone.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Mifepristone.
AlogliptinAlogliptin may increase the hypoglycemic activities of Mifepristone.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Mifepristone.
AmantadineMifepristone may increase the QTc-prolonging activities of Amantadine.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Mifepristone.
AmiodaroneMifepristone may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineMifepristone may increase the QTc-prolonging activities of Amitriptyline.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Mifepristone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mifepristone.
AmoxapineMifepristone may increase the QTc-prolonging activities of Amoxapine.
AnagrelideMifepristone may increase the QTc-prolonging activities of Anagrelide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.
ApomorphineMifepristone may increase the QTc-prolonging activities of Apomorphine.
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Mifepristone.
ArformoterolMifepristone may increase the QTc-prolonging activities of Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mifepristone.
ArmodafinilThe serum concentration of Armodafinil can be increased when it is combined with Mifepristone.
Arsenic trioxideMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.
AsenapineMifepristone may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of Mifepristone can be increased when it is combined with Atazanavir.
AtomoxetineMifepristone may increase the QTc-prolonging activities of Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Mifepristone.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Mifepristone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mifepristone.
AzithromycinMifepristone may increase the QTc-prolonging activities of Azithromycin.
BedaquilineMifepristone may increase the QTc-prolonging activities of Bedaquiline.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Mifepristone.
BetamethasoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.
BexaroteneThe serum concentration of Mifepristone can be decreased when it is combined with Bexarotene.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Mifepristone.
BoceprevirThe serum concentration of Mifepristone can be increased when it is combined with Boceprevir.
BortezomibMifepristone may increase the QTc-prolonging activities of Bortezomib.
BosentanThe serum concentration of Mifepristone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mifepristone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mifepristone.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Mifepristone.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Mifepristone.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Mifepristone.
BuserelinMifepristone may increase the QTc-prolonging activities of Buserelin.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Mifepristone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mifepristone.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Mifepristone.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Mifepristone.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Mifepristone.
CarbamazepineThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Mifepristone.
CeritinibMifepristone may increase the QTc-prolonging activities of Ceritinib.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Mifepristone.
ChloroquineMifepristone may increase the QTc-prolonging activities of Chloroquine.
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Mifepristone.
ChlorpromazineMifepristone may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Mifepristone.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Mifepristone.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Mifepristone.
CiprofloxacinMifepristone may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideMifepristone may increase the QTc-prolonging activities of Cisapride.
CitalopramMifepristone may increase the QTc-prolonging activities of Citalopram.
ClarithromycinMifepristone may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineMifepristone may increase the QTc-prolonging activities of Clomipramine.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Mifepristone.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Mifepristone.
ClozapineMifepristone may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Mifepristone can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Mifepristone.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mifepristone.
ConivaptanThe serum concentration of Mifepristone can be increased when it is combined with Conivaptan.
CorticotropinThe therapeutic efficacy of Corticotropin can be decreased when used in combination with Mifepristone.
Cortisone acetateThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Mifepristone.
CrizotinibMifepristone may increase the QTc-prolonging activities of Crizotinib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.
Cyproterone acetateThe serum concentration of Cyproterone acetate can be increased when it is combined with Mifepristone.
DabrafenibThe serum concentration of Mifepristone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Mifepristone.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Mifepristone.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Mifepristone.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Mifepristone.
DarunavirThe serum concentration of Mifepristone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Mifepristone.
DeferasiroxThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.
DegarelixMifepristone may increase the QTc-prolonging activities of Degarelix.
DesfluraneMifepristone may increase the QTc-prolonging activities of Desflurane.
DesipramineMifepristone may increase the QTc-prolonging activities of Desipramine.
DexamethasoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.
DexketoprofenThe therapeutic efficacy of Mifepristone can be decreased when used in combination with Dexketoprofen.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mifepristone.
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Mifepristone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mifepristone.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Mifepristone.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Mifepristone.
DiphenhydramineMifepristone may increase the QTc-prolonging activities of Diphenhydramine.
DisopyramideMifepristone may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mifepristone.
DofetilideMifepristone may increase the QTc-prolonging activities of Dofetilide.
DolasetronMifepristone may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.
DoxazosinThe serum concentration of Doxazosin can be increased when it is combined with Mifepristone.
DoxepinMifepristone may increase the QTc-prolonging activities of Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mifepristone.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Mifepristone.
DronedaroneMifepristone may increase the QTc-prolonging activities of Dronedarone.
DroperidolMifepristone may increase the QTc-prolonging activities of Droperidol.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mifepristone.
EliglustatMifepristone may increase the QTc-prolonging activities of Eliglustat.
EnzalutamideThe serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Mifepristone.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Mifepristone.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Mifepristone.
EribulinMifepristone may increase the QTc-prolonging activities of Eribulin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mifepristone.
ErythromycinMifepristone may increase the QTc-prolonging activities of Erythromycin.
EscitalopramMifepristone may increase the QTc-prolonging activities of Escitalopram.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Mifepristone.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Mifepristone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mifepristone.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mifepristone.
EzogabineMifepristone may increase the QTc-prolonging activities of Ezogabine.
FamotidineMifepristone may increase the QTc-prolonging activities of Famotidine.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Mifepristone.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Mifepristone.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Mifepristone.
FingolimodMifepristone may increase the QTc-prolonging activities of Fingolimod.
FlecainideMifepristone may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Mifepristone.
FluconazoleMifepristone may increase the QTc-prolonging activities of Fluconazole.
FludrocortisoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Mifepristone.
FluoxetineMifepristone may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolMifepristone may increase the QTc-prolonging activities of Flupentixol.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Mifepristone.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Mifepristone.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Mifepristone.
FormoterolMifepristone may increase the QTc-prolonging activities of Formoterol.
FosaprepitantThe serum concentration of Fosaprepitant can be increased when it is combined with Mifepristone.
FoscarnetMifepristone may increase the QTc-prolonging activities of Foscarnet.
FosphenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Mifepristone can be increased when it is combined with Fusidic Acid.
Gadobenate DimeglumineMifepristone may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
GalantamineMifepristone may increase the QTc-prolonging activities of Galantamine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mifepristone.
GemifloxacinMifepristone may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Mifepristone.
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Mifepristone.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Mifepristone.
GliquidoneGliquidone may increase the hypoglycemic activities of Mifepristone.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Mifepristone.
GoserelinMifepristone may increase the QTc-prolonging activities of Goserelin.
GranisetronMifepristone may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Mifepristone.
HaloperidolMifepristone may increase the QTc-prolonging activities of Haloperidol.
HistrelinMifepristone may increase the QTc-prolonging activities of Histrelin.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.
HydrocortisoneThe therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Mifepristone.
HydroxyzineMifepristone may increase the QTc-prolonging activities of Hydroxyzine.
IbandronateMifepristone may increase the QTc-prolonging activities of Ibandronate.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Mifepristone.
IbutilideMifepristone may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Mifepristone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Mifepristone resulting in a loss in efficacy.
IloperidoneMifepristone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mifepristone.
ImipramineMifepristone may increase the QTc-prolonging activities of Imipramine.
IndacaterolMifepristone may increase the QTc-prolonging activities of Indacaterol.
IndapamideMifepristone may increase the QTc-prolonging activities of Indapamide.
IndinavirThe serum concentration of Mifepristone can be increased when it is combined with Indinavir.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Mifepristone.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Mifepristone.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Mifepristone.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Mifepristone.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Mifepristone.
Insulin RegularInsulin Regular may increase the hypoglycemic activities of Mifepristone.
Insulin, isophaneInsulin, isophane may increase the hypoglycemic activities of Mifepristone.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mifepristone.
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Mifepristone.
IsofluraneMifepristone may increase the QTc-prolonging activities of Isoflurane.
IsosorbideThe serum concentration of Isosorbide can be increased when it is combined with Mifepristone.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Mifepristone.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Mifepristone.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Mifepristone.
ItraconazoleThe serum concentration of Mifepristone can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Mifepristone.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Mifepristone.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Mifepristone.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Mifepristone.
KetoconazoleThe serum concentration of Mifepristone can be increased when it is combined with Ketoconazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Mifepristone.
LenvatinibMifepristone may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideMifepristone may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinMifepristone may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mifepristone.
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Mifepristone.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Mifepristone.
LinagliptinLinagliptin may increase the hypoglycemic activities of Mifepristone.
LithiumMifepristone may increase the QTc-prolonging activities of Lithium.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Mifepristone.
LosartanThe serum concentration of Losartan can be increased when it is combined with Mifepristone.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Mifepristone.
LuliconazoleThe serum concentration of Mifepristone can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Mifepristone.
MACITENTANThe serum concentration of MACITENTAN can be increased when it is combined with Mifepristone.
MaprotilineMifepristone may increase the QTc-prolonging activities of Maprotiline.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Mifepristone.
Medroxyprogesterone AcetateThe therapeutic efficacy of Medroxyprogesterone Acetate can be decreased when used in combination with Mifepristone.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Mifepristone.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Mifepristone.
MetforminMetformin may increase the hypoglycemic activities of Mifepristone.
MethadoneMifepristone may increase the QTc-prolonging activities of Methadone.
MethotrimeprazineMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.
MethylprednisoloneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.
MetoclopramideMifepristone may increase the QTc-prolonging activities of Metoclopramide.
MetronidazoleMifepristone may increase the QTc-prolonging activities of Metronidazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mifepristone.
MirabegronMifepristone may increase the QTc-prolonging activities of Mirabegron.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Mifepristone can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Mifepristone.
MoexiprilMifepristone may increase the QTc-prolonging activities of Moexipril.
MoxifloxacinMifepristone may increase the QTc-prolonging activities of Moxifloxacin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mifepristone.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Mifepristone.
NefazodoneThe serum concentration of Mifepristone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Mifepristone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Mifepristone can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Mifepristone.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mifepristone.
NilotinibMifepristone may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Mifepristone.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Mifepristone.
NorethindroneThe therapeutic efficacy of Norethindrone can be decreased when used in combination with Mifepristone.
NorfloxacinMifepristone may increase the QTc-prolonging activities of Norfloxacin.
NortriptylineMifepristone may increase the QTc-prolonging activities of Nortriptyline.
OctreotideMifepristone may increase the QTc-prolonging activities of Octreotide.
OfloxacinMifepristone may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineMifepristone may increase the QTc-prolonging activities of Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Mifepristone.
OlodaterolMifepristone may increase the QTc-prolonging activities of Olodaterol.
OndansetronMifepristone may increase the QTc-prolonging activities of Ondansetron.
OsimertinibMifepristone may increase the QTc-prolonging activities of Osimertinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Mifepristone.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Mifepristone.
OxytocinMifepristone may increase the QTc-prolonging activities of Oxytocin.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Mifepristone.
PaliperidoneMifepristone may increase the QTc-prolonging activities of Paliperidone.
PanobinostatMifepristone may increase the QTc-prolonging activities of Panobinostat.
ParoxetineMifepristone may increase the QTc-prolonging activities of Paroxetine.
PasireotideMifepristone may increase the QTc-prolonging activities of Pasireotide.
PazopanibMifepristone may increase the QTc-prolonging activities of Pazopanib.
PegvisomantPegvisomant may increase the hypoglycemic activities of Mifepristone.
PentamidineMifepristone may increase the QTc-prolonging activities of Pentamidine.
PerflutrenMifepristone may increase the QTc-prolonging activities of Perflutren.
PhenelzinePhenelzine may increase the hypoglycemic activities of Mifepristone.
PhenobarbitalThe serum concentration of Mifepristone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Phenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Mifepristone.
PimozideMifepristone may increase the QTc-prolonging activities of Pimozide.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Mifepristone.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Mifepristone.
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.
PosaconazoleThe serum concentration of Mifepristone can be increased when it is combined with Posaconazole.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Mifepristone.
PrednisoloneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.
PrednisoneThe therapeutic efficacy of Prednisone can be decreased when used in combination with Mifepristone.
PrimaquineMifepristone may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Mifepristone can be decreased when it is combined with Primidone.
ProcainamideMifepristone may increase the QTc-prolonging activities of Procainamide.
PromazineMifepristone may increase the QTc-prolonging activities of Promazine.
PromethazineMifepristone may increase the QTc-prolonging activities of Promethazine.
PropafenoneMifepristone may increase the QTc-prolonging activities of Propafenone.
PropofolMifepristone may increase the QTc-prolonging activities of Propofol.
ProtriptylineMifepristone may increase the QTc-prolonging activities of Protriptyline.
QuetiapineMifepristone may increase the QTc-prolonging activities of Quetiapine.
QuinidineMifepristone may increase the QTc-prolonging activities of Quinidine.
QuinineMifepristone may increase the QTc-prolonging activities of Quinine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mifepristone.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Mifepristone.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Mifepristone.
Repository corticotropinThe therapeutic efficacy of Repository corticotropin can be decreased when used in combination with Mifepristone.
RifabutinThe serum concentration of Mifepristone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Mifepristone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Mifepristone can be decreased when it is combined with Rifapentine.
RilpivirineMifepristone may increase the QTc-prolonging activities of Rilpivirine.
RisperidoneMifepristone may increase the QTc-prolonging activities of Risperidone.
RitonavirThe serum concentration of Mifepristone can be increased when it is combined with Ritonavir.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Mifepristone.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Mifepristone.
SalbutamolMifepristone may increase the QTc-prolonging activities of Salbutamol.
Salicylate-sodiumSalicylate-sodium may increase the hypoglycemic activities of Mifepristone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Mifepristone.
SaquinavirMifepristone may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Mifepristone.
SertralineMifepristone may increase the QTc-prolonging activities of Sertraline.
SevofluraneMifepristone may increase the QTc-prolonging activities of Sevoflurane.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Mifepristone.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.
SiltuximabThe serum concentration of Mifepristone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Mifepristone.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Mifepristone.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Mifepristone.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Mifepristone.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Mifepristone.
SorafenibMifepristone may increase the QTc-prolonging activities of Sorafenib.
SotalolMifepristone may increase the QTc-prolonging activities of Sotalol.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Mifepristone.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Mifepristone.
St. John's WortThe serum concentration of Mifepristone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mifepristone can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Mifepristone.
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Mifepristone.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Mifepristone.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Mifepristone.
TacrolimusMifepristone may increase the QTc-prolonging activities of Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Mifepristone.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mifepristone.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Mifepristone.
TelaprevirThe serum concentration of Mifepristone can be increased when it is combined with Telaprevir.
TelavancinMifepristone may increase the QTc-prolonging activities of Telavancin.
TelithromycinMifepristone may increase the QTc-prolonging activities of Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mifepristone.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Mifepristone.
TerbutalineMifepristone may increase the QTc-prolonging activities of Terbutaline.
TestosteroneTestosterone may increase the hypoglycemic activities of Mifepristone.
TetrabenazineMifepristone may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Mifepristone.
ThioridazineMifepristone may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneMifepristone may increase the QTc-prolonging activities of Thiothixene.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Mifepristone.
TizanidineMifepristone may increase the QTc-prolonging activities of Tizanidine.
TocilizumabThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Mifepristone.
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Mifepristone.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Mifepristone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mifepristone.
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.
ToremifeneMifepristone may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Mifepristone.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Mifepristone.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Mifepristone.
TreprostinilMifepristone may increase the QTc-prolonging activities of Treprostinil.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Mifepristone.
TriamcinoloneThe therapeutic efficacy of Triamcinolone can be decreased when used in combination with Mifepristone.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Mifepristone.
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Mifepristone.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.
TriptorelinMifepristone may increase the QTc-prolonging activities of Triptorelin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mifepristone.
VandetanibMifepristone may increase the QTc-prolonging activities of Vandetanib.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Mifepristone.
VemurafenibMifepristone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mifepristone.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Mifepristone.
VildagliptinVildagliptin may increase the hypoglycemic activities of Mifepristone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mifepristone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Mifepristone.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Mifepristone.
VoriconazoleThe serum concentration of Mifepristone can be increased when it is combined with Voriconazole.
VorinostatMifepristone may increase the QTc-prolonging activities of Vorinostat.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Mifepristone.
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Mifepristone.
ZiprasidoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Mifepristone.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Mifepristone.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Mifepristone.
ZuclopenthixolMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

1. Progesterone receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Progesterone receptor P06401 Details

References:

  1. Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, Wallwiener D: Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod. 1999 Jan;14(1):198-206. Pubmed
  2. Sun M, Zhu G, Zhou L: [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata] Zhonghua Fu Chan Ke Za Zhi. 1998 Apr;33(4):227-31. Pubmed
  3. Hazra BG, Basu S, Pore VS, Joshi PL, Pal D, Chakrabarti P: Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486). Steroids. 2000 Mar;65(3):157-62. Pubmed
  4. Gao Y, Cheng L, Liu Y: [Failure of mifepristone induced interruption of pregnancy: point mutation at genetic codon 722 in human progesterone receptor gene] Zhonghua Fu Chan Ke Za Zhi. 1998 Sep;33(9):549-52. Pubmed
  5. Jiang J, Wu R, Wang Z: [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria] Zhonghua Fu Chan Ke Za Zhi. 2001 Apr;36(4):218-21. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Glucocorticoid receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. LeVan TD, Babin EA, Yamamura HI, Bloom JW: Pharmacological characterization of glucocorticoid receptors in primary human bronchial epithelial cells. Biochem Pharmacol. 1999 May 1;57(9):1003-9. Pubmed
  2. Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. Pubmed
  3. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. Pubmed
  4. Gu G, Hentunen TA, Nars M, Harkonen PL, Vaananen HK: Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis. 2005 May;10(3):583-95. Pubmed
  5. de Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A: Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006 May 24;26(21):5709-19. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. Pubmed
  2. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994 Nov 28;355(2):187-91. Pubmed

2. Multidrug resistance-associated protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 1 P33527 Details

References:

  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 29, 2013 15:39